Physician profile
Dilipkumar C Patel
NPI 1033172473
$3,309.94
in general payments reported to CMS, 2019-2025
30 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $231 · 2021: $593 · 2022: $1,056 · 2023: $208 · 2024: $180 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $463.65 | 2019-2022 | |
| Glaxosmithkline, LLC. | $372.09 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $342.70 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $275.71 | 2021-2023 | |
| Novo Nordisk INC | $231.26 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $222.84 | 2020-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.76 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $159.60 | 2019-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $156.23 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $115.45 | 2019-2022 | |
| Vifor Pharma, INC. | $113.56 | 2024-2025 | Zemaira, Veltassa |
| Exact Sciences Corporation | $106.19 | 2023-2025 | Cologuard Collection Kit |
| Cumberland Pharmaceuticals, INC. | $84.41 | 2022-2023 | Kristalose |
| Novartis Pharmaceuticals Corporation | $70.09 | 2019-2022 | |
| Amgen INC. | $57.78 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $40.21 | 2019-2021 | |
| Pfizer INC. | $40.20 | 2019-2021 | |
| Eisai INC. | $25.87 | 2024 | |
| Genzyme Corporation | $25.60 | 2023 | |
| Amarin Pharma, INC. | $24.82 | 2019 | |
| Vanda Pharmaceuticals INC. | $24.28 | 2019 | |
| Astellas Pharma US INC | $23.13 | 2019 | |
| Abbott Laboratories | $20.00 | 2022 | |
| Seqirus USA INC | $19.58 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.31 | 2021 | |
| Allergan, INC. | $17.63 | 2019 | |
| Shield Therapeutics INC | $17.40 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.52 | 2023 | Seglentis |
| Phadia US INC. | $13.22 | 2022 | |
| Janssen Biotech, INC. | $9.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilipkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.